Wedbush raised the firm’s price target on Xencor to $36 from $34 and keeps an Outperform rating on the shares. With robust partnership developments, promising early data for vudalimab, and a strong cash position to support ongoing programs, Wedbush believes Xencor shares are attractive at current levels.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR: